Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer

Jan B. Vermorken, Fernando Rivera, Éva Remenár, +14

New England Journal of Medicine

Cisplatin, Fluorouracil, and Docetaxel in Unresectable Head and Neck Cancer

Jan B. Vermorken, Éva Remenár, Carla van Herpen, +14

New England Journal of Medicine

Phase II Trial of Weekly Paclitaxel for Unresectable Angiosarcoma: The ANGIOTAX Study

Nicolas Penel, Binh Bui, Jacques‐Olivier Bay, +13

Journal of Clinical Oncology

Randomised trial of interferon α-2a as adjuvant therapy in resected primary melanoma thicker than 1·5 mm without clinically detectable node metastases

Jean‐Jacques Grob, Brigitte Dréno, Pauline de La Salmonière, +10

The Lancet

Surgical OncologyDetectable Node MetastasesMedicineMelanomaImmunology +4

Prospective Multicentric Randomized Phase III Study of Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors Comparing Interruption Versus Continuation of Treatment Beyond 1 Year: The French Sarcoma Group

Jean‐Yves Blay, Axel Le Cesne, Isabelle Ray‐Coquard, +14

Journal of Clinical Oncology

Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial

Jean-Pascal H. Machiels, Robert I. Haddad, Jérôme Fayette, +16

The Lancet Oncology

Neoadjuvant TherapyNeck 1Randomised Phase 3MedicineHead And Neck Cancer +8

Improved survival using specialized multidisciplinary board in sarcoma patients

Jean‐Yves Blay, Pauline Soibinet, Nicolas Penel, +27

Annals of Oncology

Surgical OncologySpecialized Multidisciplinary BoardMedicineCancer ManagementPrognosis +3

Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial

Axel Le Cesne, Isabelle Ray‐Coquard, Binh Bui, +11

The Lancet Oncology

Gastrointestinal OncologyMedicineGastroenterologyPathologyOpen-label Multicentre +6

Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial

Olivier Mir, Thomas Brodowicz, Antoîne Italiano, +27

The Lancet Oncology

OncologyMetronomic TherapyClinical TrialsPharmacotherapyCancer Treatment +3

Final report of the french multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases

C Jacquillat, D. Khayat, Pierre Banzet, +14

Cancer

Neuro-oncologySurgical OncologyMedicineFinal ReportDisseminated Malignant Melanoma +9